Data were obtained from medical records and national health insurance data over 5 years, released by the Department of Medical Financial Services at the University of Ryukyus Hospital. The costs were adjusted to 2006 values using the consumer price index for the Okinawa prefecture in Japan for ...
Bladder Cancer By END USER Pediatrics Adults By Region North America(U.S., Canada, Mexico) Europe(France, Germany, Italy, Spain, UK, Russia, Rest of Europe) Asia-Pacific(China, Japan, India, South Korea, Australia, Thailand, Malaysia, Indonesia, Rest of Asia-Pacific) ...
the development of BCG-resistant bladder cancer remains a major setback. Thus, there is an urgent need for a major effective therapy for bladder cancer patients who are unresponsive to BCG immunotherapy. This chapter summarizes briefly the recent highlights and advances in BCG immunotherapy against NM...
bladder cancer burdens. Additionally, hospitals provide advantages such as low-cost diagnostic procedures, surgeries, medication availability, and state-of-the-art infrastructure, which contribute to their market leadership. The segment is also experiencing the fastest growth rate of around 7% for the ...
Probably the most abundant use of BCG in cancer therapy is in bladder cancer. Intravesical administration is used for three purposes: 1) adjunctive therapy as a single treatment after complete tumor resolution to prevent tumor cell implantation and recurrence; 2) prophylactically, in repeated ...
BCG-RIVM strain was used in many treatment protocols for non-muscle invasive bladder cancer only as induction courses. Cho et al. (Anticancer Res 2012) compared BCG-RIVM induction and 'standard' maintenance (Lamm et al., J Urol. 2000) to mitomycin C. They found no statistically significant ...
QALY gains in Gemcitabine/Docetaxel and especially HIVEC were mainly driven by bladder preservation and the low rate of progression.Conclusions:Considering a WTP of <50.000 Euro / QALY, Gemcitabine/Docetaxel and HIVEC are highly cost-effective therapy options in BCG unresponsive bladder cancer, while...
Lamm DL, Thor DE, Stogdill VD, Radwin HM (1982) Bladder cancer immunotherapy. J Urol 128:931–935 Google Scholar Veenema RJ, Dean AL, Uson AC, Roberts M, Longo E (1969) Thio-tepa bladder instillations: Therapy and prophylaxis for superficial bladder tumors. J Urol 101:711 Google Schol...
BCG immunotherapy is currently the most effective treatment for superficial transitional cell carcinoma of the urinary bladder and is also used worldwide in vaccination programs against tuberculosis.This is a preview of subscription content, log in via an institution to check access. ...
Disseminated Mycobacterium bovis infection post-kidney transplant following remote intravesical BCG therapy for bladder cancer. Transplant Infectious Disease 20: No. 5, Oct 2018. Available from: URL: http://doi.org/10.1111/tid.12931 - Canada Download references Rights and permissions Reprints and ...